LeMaitre Vascular (LMAT) Q1 Earnings Preview: What Investors Should Watch This Week
LeMaitre Vascular (NASDAQ:LMAT), a niche player in the medical device space focused on vascular surgery, is scheduled to release its first-quarter earnings after market close on Tuesday. The report comes at a time when the broader healthcare equipment sector has seen a modest uptick in investor sentiment, though LeMaitre’s stock has remained flat over the past month.
In the previous quarter, LeMaitre delivered revenue of $64.45 million, a 15.7% year-over-year increase, beating analyst expectations. The company also exceeded EPS guidance for the next quarter and full-year estimates, marking a strong performance. However, the company has a mixed track record when it comes to revenue forecasts—having missed Wall Street’s expectations multiple times over the last two years.
For this quarter, analysts project revenue growth of 11.4% year over year, which is roughly in line with the 12% growth recorded in the same period last year. Most analysts have maintained their estimates over the past 30 days, signaling confidence that LeMaitre will stay on course. The average analyst price target currently sits at $111.22, compared to the stock’s recent price of $108.97.
Looking at the broader landscape, LeMaitre’s peers in the healthcare equipment and supplies segment have already reported their Q1 numbers, offering a glimpse into industry trends. Intuitive Surgical posted a 23% revenue jump, beating estimates by 5.8%, while Baxter reported a 2.9% revenue increase, topping expectations by 3.5%. Both stocks rose following their reports—Intuitive Surgical climbed 7.2%, and Baxter gained 1.6%.
“LeMaitre is a steady player, but it’s not a growth rocket like Intuitive Surgical. The real question is whether they can sustain margins and keep up with hospital demand,” said Michael Torres, a healthcare analyst at Pinnacle Research Group.
“I’m tired of hearing ‘in line with expectations’—this company needs to show it can actually accelerate, not just coast. If they miss again, the stock is going to get hammered,” said Rachel Kim, a retail investor and frequent commentator on medical device stocks.
“The vascular surgery market is growing, but LeMaitre faces increasing competition from larger players. Tuesday’s report will be a key test of whether they can hold their ground,” noted Dr. James Hartfield, a former vascular surgeon turned industry consultant.
Despite the cautious tone, the healthcare equipment segment has seen share prices rise an average of 6% over the last month. LeMaitre’s stock has been flat during the same period, suggesting that investors are waiting for a catalyst—either positive or negative—from this earnings release.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable. These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.